Author:
Boquoi A.,Banahan S. M.,Mohring A.,Savickaite I.,Strapatsas J.,Hildebrandt B.,Kobbe G.,Gattermann N.,Haas R.,Schroeder T.,Germing U.,Fenk R.
Abstract
AbstractMyelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) can be late complications following mutagenic treatment. Limited data is available on the outcome of patients developing therapy-related MDS and AML after treatment for multiple myeloma (MM). We identified 250 patients with therapy-associated MDS or AML in the Duesseldorf MDS registry. Of those, 50 patients were previously diagnosed with multiple myeloma (mm-MDS/AML). We compared them to patients with de novo MDS (n = 4862) and to patients with MDS following other underlying diseases (tMDS) (n = 200). mm-MDS patients and tMDS patients showed similar karyotypes and degrees of cytopenia. However, mm-MDS patients had significantly higher blast counts and more often belonged to the high-risk group according to the International Prognostic Scoring System (IPSS) (both p < 0.05). Although the rate of progression to AML was similar in mm-MDS and tMDS, both transformed significantly more often than de novo MDS (p < 0.05). Median overall survival of patients with mm-MDS (13 months; range: 1–99) and tMDS (13 months; range 0–160) was also similar yet significantly shorter than patients with de novo MDS (32 months; range 0–345 months; p < 0.05). Furthermore, survival of mm-MDS patients was not affected by myeloma activity. Despite significantly more high-risk disease and higher blast cell counts, myeloma-associated MDS-patients show features akin to other tMDS. Survival is similar to other tMDS and irrespective of myeloma remission status or transformation to AML. Thus, patient outcome is not determined by competing clones but rather by MDS governing the stem cell niche.
Funder
Universitätsklinikum Düsseldorf. Anstalt öffentlichen Rechts
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference41 articles.
1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544
2. Leone G, Pagano L, Ben-Yehuda D, Voso MT (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92(10):1389–1398
3. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U, Gattermann N (2005) Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haematologica 90(5):691–693
4. Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR et al (2004) Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 104(3):822–828
5. Schroeder T, Kuendgen A, Kayser S et al (2012) Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica 97(2):206–212. https://doi.org/10.3324/haematol.2011.049114
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献